Company intelligence

CGEN

Compugen Ltd. · NASDAQ · Healthcare

Price$2.90+0.87% · +$0.03

Market cap273.73MEquity value

P / E7.6Trailing ratio

Volume154.23KLatest session

Market data

CGEN price chart

TradingView

Related signals

1 min delayed

Browse public CGEN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CGENJul 29, 2024

AI 29 July 2024 Pre-Market Analysis | CGEN

FDA clearance triggers a $30 million milestone payment from Gilead. Positive expectations for upcoming Phase 1 trial initiation. The approval positions COM503 as a first-in-class treatment.

View signal analysis

CGENMay 20, 2024-11.61% since signal

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

- Compugen reported a quarterly loss of $0.08 per share, beating estimates by 20%. - Revenues for the quarter totaled $2.56 million, missing estimates by 8.28%. - Compugen shares have gained 6.6% this year, underperforming the S&P 500. - Estimate revisions trend for Compugen is currently mixed, with a Zacks Rank #3 (Hold). - Industry outlook can impact stock performance, Medical - Biomedical and Genetics ranks in top 35%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Research Analysis

View signal analysis

Research